
Histogen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update
Strengthened Balance Sheet with $25.3 Million of Gross Proceeds from Financings and Warrant Exercises Initiation of Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients Anticipated in the First Quarter of 2021 HST 003 Trial Initiation for Cartilage …